Tumefactive multiple sclerosis lesions under fingolimod treatment
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Fingolimod is an oral sphingosine 1-phosphate receptor modulator that prevents recirculation of lymphocyte subsets from lymph nodes. It decreases the number of relapses, slows the progression of disability, and improves MRI endpoints in patients with relapsing-remitting multiple sclerosis (RRMS).1 Infrequent but specific side effects are bradycardia, leukopenia, and macular edema.
Case report.
In November 2010, a 23-year-old woman with RRMS since September 2007 started fingolimod 0.5 mg per day in the setting of the open-label FTY720D2316 trial. Interferon-β treatment was initiated in 2008, but discontinued mid-2010 because of side effects. Her disease course was relatively mild with low frequency and complete recovery of relapses. In March 2011, she presented with a left-sided hemiparesis, headache, and nausea that had gradually developed over 2 weeks. Because she had no clinical signs of infection, an exacerbation of multiple sclerosis (MS) was considered initially and she was admitted for IV methylprednisolone …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Late development of tumefactive lesions associated with fingolimod.
- Michael O. Kinney, Neurology Registrar, Royal Victoria Hospital, Belfast, Northern Ireland.mickinney@gmail.com
- Gavin McDonnell, Neurology Consultant.
Submitted December 27, 2012 - Safety monitoring of MS patients treated with fingolimod: a story beyond opportunistic infections
- Mike P. Wattjes, Radiologist, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlandsm.wattjes@vumc.nl
- Mike P. Wattjes, Femke Visser, Bob W. van Oosten
Submitted December 27, 2012
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Editorials
Fingolimod and multiple sclerosisFour cautionary talesDennis Bourdette, Don Gilden et al.Neurology, October 03, 2012 -
New Drugs and Devices
FingolimodMegan H. Hyland, Jeffrey A. Cohen et al.Neurology: Clinical Practice, December 01, 2011 -
Articles
Future clinical challenges in multiple sclerosisRelevance to sphingosine 1-phosphate receptor modulator therapyReinhard Hohlfeld, Frederik Barkhof, Chris Polman et al.Neurology, February 21, 2011 -
Clinical/Scientific Notes
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimodClaus Michael Gross, Annette Baumgartner, Sebastian Rauer et al.Neurology, October 03, 2012